MINE-ESHAP联合方案治疗难治或复发性非霍奇金淋巴瘤28例

 目的　探讨MINE-ESHAP联合方案治疗难治性或复发性非霍奇金淋巴瘤（NHL）的疗效。方法　采用MINE-ESHAP联合方案治疗难治性或复发性NHL 28例。结果　28例患者中，CR 11例（39.3 %），PR 6例（21.4 %），SD 5例（17.9 %），进展或恶化5例（17.9 %），中位生存时间28.5个月。1例死于骨髓抑制期感染（3.6 %）。不良反应主要为消化道症状和骨髓抑制。结论　MINE-ESHAP方案对部分难治性或复发性NHL患者有效，不良反应可以耐受，可用于对其他化疗方案无效的难治性或复发性NHL。

Effect of MINE-ESHAP regimen in treatment of refractory or relapsed non-Hodgkin lymphoma

Objective To evaluate the efficacy of MINE-ESHAP regimen in treatment of refractory and relapsed non-Hodgkin lymphoma (NHL). Methods Twenty-eight patients with refractory and relapsed NHL were treated with MINE-ESHAP regimen. Results The rate of complete remission was 39.3 %(11/28),of partial remission 21.4 %(6/28),of stable disease 17.9 %(5/28),and of progression 17.94 %(5/28). The midsurvival time was 28.5 months. One patient died of infection during marrow restrain period. The main toxicities included gastrointestinal symptoms and myelosuppression. Conclusion MINE-ESHAP regimen is sate and could be employed in treatment of the patients with refractory and relapsed NHL.